Krystal Biotech Current Deferred Revenue (Quarterly) Analysis

Krystal Biotech, Inc. (KRYS)

253.68 +1.51 (+0.60%) USD | NASDAQ | Dec 29, 16:00

253.67 -0.01 (-0.00%) Pre-Market: 20:00

View Current Deferred Revenue (Quarterly) for KRYS.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Current Deferred Revenue (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Current Deferred Revenue (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Current Deferred Revenue (Quarterly) Benchmarks

Start Trial

DexCom, Inc.	Upgrade
Alnylam Pharmaceuticals, Inc.	Upgrade
Vanda Pharmaceuticals, Inc.	--
ADMA Biologics, Inc.	Upgrade
Aldeyra Therapeutics, Inc.	Upgrade